Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes.

45 Surprisingly, men were set more aggressive targets than women (p=0.026; Figure 2 ), whereas setting targets according to the frailty status demonstrated only a trend towards significance (p=0.068). 46 In non-frail patients, the baseline weight predicted a less aggressive glycaemic target setting (p=0.012), while astonishingly, glycaemic targets were not adjusted according to the body weight in frail patients (p=0.725; Figure 3 ). 46 The INTERVAL study was conducted before any national guidelines advocated individualising therapeutic goals.

also in 2,760 other papers